HIV-1 Antiretroviral Drug Resistance Mutations in Treatment Naïve and Experienced Panamanian Subjects: Impact on National Use of EFV-Based Schemes

Detalhes bibliográficos
Autor(a) principal: Mendoza, Yaxelis
Data de Publicação: 2016
Outros Autores: Mewa, Juan Castillo, Martínez, Alexander A., Zaldivar, Yamitzel, Sosa, Néstor, Arteaga, Griselda, Armién, Blas, Bautista, Christian T., Garcia-Morales, Claudia, Tapia-Trejo, Daniela, Ávila-Ríos, Santiago, Reyes-Terán, Gustavo, Bello, Gustavo, Pascale, Juan M.
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Repositório Institucional da FIOCRUZ (ARCA)
Texto Completo: https://www.arca.fiocruz.br/handle/icict/14427
Resumo: Gorgas Memorial Institute for Health Studies. Direction of Research and Technological Development. Panama City, Panama / Acharya Nagarjuna University. Department of Biotechnology. Guntur City, India / University of Panama. School of Biology. Department of Genetics and Molecular Biology. Panama City, Panama / Institute for Scientific Research and High Technology Services of Panama. Panama City, Panama.
id CRUZ_f5374d15671f046773090a74f97fcc69
oai_identifier_str oai:www.arca.fiocruz.br:icict/14427
network_acronym_str CRUZ
network_name_str Repositório Institucional da FIOCRUZ (ARCA)
repository_id_str 2135
spelling Mendoza, YaxelisMewa, Juan CastilloMartínez, Alexander A.Zaldivar, YamitzelSosa, NéstorArteaga, GriseldaArmién, BlasBautista, Christian T.Garcia-Morales, ClaudiaTapia-Trejo, DanielaÁvila-Ríos, SantiagoReyes-Terán, GustavoBello, GustavoPascale, Juan M.2016-06-02T13:36:33Z2016-06-03T12:34:16Z2016-06-02T13:36:33Z2016-06-03T12:34:16Z2016MENDOZA, Yaxelis; et al. HIV-1 Antiretroviral Drug Resistance Mutations in Treatment Naïve and Experienced Panamanian Subjects: Impact on National Use of EFV-Based Schemes. Plos One, v.11, n.4, 19, Apr. 2016.1932-6203https://www.arca.fiocruz.br/handle/icict/1442710.1371/journal. pone.0154317engPublic Library of ScienceHIVTerapia anti-retroviralResistência a MedicamentosPanamáAidsHIV-1Antiretroviral Drug ResistancePanamaAIDSHIV-1 Antiretroviral Drug Resistance Mutations in Treatment Naïve and Experienced Panamanian Subjects: Impact on National Use of EFV-Based Schemesinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleGorgas Memorial Institute for Health Studies. Direction of Research and Technological Development. Panama City, Panama / Acharya Nagarjuna University. Department of Biotechnology. Guntur City, India / University of Panama. School of Biology. Department of Genetics and Molecular Biology. Panama City, Panama / Institute for Scientific Research and High Technology Services of Panama. Panama City, Panama.Gorgas Memorial Institute for Health Studies. Direction of Research and Technological Development. Panama City, Panama.Gorgas Memorial Institute for Health Studies. Direction of Research and Technological Development. Panama City, Panama / Acharya Nagarjuna University. Department of Biotechnology. Guntur City, India / Institute for Scientific Research and High Technology Services of Panama. Panama City, Panama.Gorgas Memorial Institute for Health Studies. Direction of Research and Technological Development. Panama City, Panama.Gorgas Memorial Institute for Health Studies. Direction of Research and Technological Development. Panama City, Panama.University of Panama. School of Medicine. Department of Microbiology. Panama City, Panama.Gorgas Memorial Institute for Health Studies. Direction of Research and Technological Development. Panama City, Panama / Universidad Interamericana de Panamá. Facultad de Ciencias de la Salud. Panama City, Panama.Gorgas Memorial Institute for Health Studies. Direction of Research and Technological Development. Panama City, Panama.National Institute of Respiratory Diseases (Centro de Investigación en Enfermedades Infecciosas, Instituto Nacional de Enfermedades Respiratorias). Centre for Research in Infectious Diseases. Mexico City, Mexico.National Institute of Respiratory Diseases (Centro de Investigación en Enfermedades Infecciosas, Instituto Nacional de Enfermedades Respiratorias). Centre for Research in Infectious Diseases. Mexico City, Mexico.National Institute of Respiratory Diseases (Centro de Investigación en Enfermedades Infecciosas, Instituto Nacional de Enfermedades Respiratorias). Centre for Research in Infectious Diseases. Mexico City, Mexico.National Institute of Respiratory Diseases (Centro de Investigación en Enfermedades Infecciosas, Instituto Nacional de Enfermedades Respiratorias). Centre for Research in Infectious Diseases. Mexico City, Mexico.Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de AIDS e Imunologia Molecular. Rio de Janeiro, RJ, Brasil.Gorgas Memorial Institute for Health Studies. Direction of Research and Technological Development. Panama City, Panama / University of Panama. School of Medicine. Department of Microbiology. Panama City, Panama.The use of antiretroviral therapy in HIV infected subjects prevents AIDS-related illness and delayed occurrence of death. In Panama, rollout of ART started in 1999 and national coverage has reached 62.8% since then. The objective of this study was to determine the level and patterns of acquired drug resistance mutations of clinical relevance (ADR-CRM) and surveillance drug resistance mutations (SDRMs) from 717 HIV-1 pol gene sequences obtained from 467 ARV drug-experienced and 250 ARV drug-naïve HIV-1 subtypes B infected subjects during 2007–2013, respectively. The overall prevalence of SDRM and of ADR-CRM during the study period was 9.2% and 87.6%, respectively. The majority of subjects with ADR-CRM had a pattern of mutations that confer resistance to at least two classes of ARV inhibitors. The non-nucleoside reverse transcriptase inhibitor (NNRTI) mutations K103N and P225H were more prevalent in both ARV drug-naïve and ARV drugexperienced subjects. The nucleoside reverse transcriptase inhibitor (NRTI) mutation M184V was more frequent in ARV drug-experienced individuals, while T215YFrev and M41L were more frequent in ARV drug-naïve subjects. Prevalence of mutations associated to protease inhibitors (PI) was lower than 4.1% in both types of subjects. Therefore, there is a high level of resistance (>73%) to Efavirenz/Nevirapine, Lamivudine and Azidothymidine in ARV drug-experienced subjects, and an intermediate to high level of resistance (5–10%) to Efavirenz/Nevirapine in ARV drug-naïve subjects. During the study period, we observed an increasing trend in the prevalence of ADR-CRM in subjects under first-line schemes, but not significant changes in the prevalence of SDRM. These results reinforce the paramount importance of a national surveillance system of ADR-CRM and SDRM for national management policies of subjects living with HIV.info:eu-repo/semantics/openAccessreponame:Repositório Institucional da FIOCRUZ (ARCA)instname:Fundação Oswaldo Cruz (FIOCRUZ)instacron:FIOCRUZORIGINALgonzalo_bello_etal_IOC_2016.PDFapplication/pdf3009122https://www.arca.fiocruz.br/bitstream/icict/14427/1/gonzalo_bello_etal_IOC_2016.PDF9ac1aecdba0a8337eef8acb1440348dbMD51LICENSElicense.txttext/plain2991https://www.arca.fiocruz.br/bitstream/icict/14427/2/license.txt5a560609d32a3863062d77ff32785d58MD52TEXTgonzalo_bello_etal_IOC_2016.PDF.txtgonzalo_bello_etal_IOC_2016.PDF.txtExtracted texttext/plain56495https://www.arca.fiocruz.br/bitstream/icict/14427/3/gonzalo_bello_etal_IOC_2016.PDF.txt83ecd2fc071497f6e5f2cb52f404be0cMD53icict/144272022-06-24 13:08:45.168oai:www.arca.fiocruz.br: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ório InstitucionalPUBhttps://www.arca.fiocruz.br/oai/requestrepositorio.arca@fiocruz.bropendoar:21352022-06-24T16:08:45Repositório Institucional da FIOCRUZ (ARCA) - Fundação Oswaldo Cruz (FIOCRUZ)false
dc.title.pt_BR.fl_str_mv HIV-1 Antiretroviral Drug Resistance Mutations in Treatment Naïve and Experienced Panamanian Subjects: Impact on National Use of EFV-Based Schemes
title HIV-1 Antiretroviral Drug Resistance Mutations in Treatment Naïve and Experienced Panamanian Subjects: Impact on National Use of EFV-Based Schemes
spellingShingle HIV-1 Antiretroviral Drug Resistance Mutations in Treatment Naïve and Experienced Panamanian Subjects: Impact on National Use of EFV-Based Schemes
Mendoza, Yaxelis
HIV
Terapia anti-retroviral
Resistência a Medicamentos
Panamá
Aids
HIV-1
Antiretroviral Drug Resistance
Panama
AIDS
title_short HIV-1 Antiretroviral Drug Resistance Mutations in Treatment Naïve and Experienced Panamanian Subjects: Impact on National Use of EFV-Based Schemes
title_full HIV-1 Antiretroviral Drug Resistance Mutations in Treatment Naïve and Experienced Panamanian Subjects: Impact on National Use of EFV-Based Schemes
title_fullStr HIV-1 Antiretroviral Drug Resistance Mutations in Treatment Naïve and Experienced Panamanian Subjects: Impact on National Use of EFV-Based Schemes
title_full_unstemmed HIV-1 Antiretroviral Drug Resistance Mutations in Treatment Naïve and Experienced Panamanian Subjects: Impact on National Use of EFV-Based Schemes
title_sort HIV-1 Antiretroviral Drug Resistance Mutations in Treatment Naïve and Experienced Panamanian Subjects: Impact on National Use of EFV-Based Schemes
author Mendoza, Yaxelis
author_facet Mendoza, Yaxelis
Mewa, Juan Castillo
Martínez, Alexander A.
Zaldivar, Yamitzel
Sosa, Néstor
Arteaga, Griselda
Armién, Blas
Bautista, Christian T.
Garcia-Morales, Claudia
Tapia-Trejo, Daniela
Ávila-Ríos, Santiago
Reyes-Terán, Gustavo
Bello, Gustavo
Pascale, Juan M.
author_role author
author2 Mewa, Juan Castillo
Martínez, Alexander A.
Zaldivar, Yamitzel
Sosa, Néstor
Arteaga, Griselda
Armién, Blas
Bautista, Christian T.
Garcia-Morales, Claudia
Tapia-Trejo, Daniela
Ávila-Ríos, Santiago
Reyes-Terán, Gustavo
Bello, Gustavo
Pascale, Juan M.
author2_role author
author
author
author
author
author
author
author
author
author
author
author
author
dc.contributor.author.fl_str_mv Mendoza, Yaxelis
Mewa, Juan Castillo
Martínez, Alexander A.
Zaldivar, Yamitzel
Sosa, Néstor
Arteaga, Griselda
Armién, Blas
Bautista, Christian T.
Garcia-Morales, Claudia
Tapia-Trejo, Daniela
Ávila-Ríos, Santiago
Reyes-Terán, Gustavo
Bello, Gustavo
Pascale, Juan M.
dc.subject.other.pt_BR.fl_str_mv HIV
Terapia anti-retroviral
Resistência a Medicamentos
Panamá
Aids
topic HIV
Terapia anti-retroviral
Resistência a Medicamentos
Panamá
Aids
HIV-1
Antiretroviral Drug Resistance
Panama
AIDS
dc.subject.en.pt_BR.fl_str_mv HIV-1
Antiretroviral Drug Resistance
Panama
AIDS
description Gorgas Memorial Institute for Health Studies. Direction of Research and Technological Development. Panama City, Panama / Acharya Nagarjuna University. Department of Biotechnology. Guntur City, India / University of Panama. School of Biology. Department of Genetics and Molecular Biology. Panama City, Panama / Institute for Scientific Research and High Technology Services of Panama. Panama City, Panama.
publishDate 2016
dc.date.accessioned.fl_str_mv 2016-06-02T13:36:33Z
2016-06-03T12:34:16Z
dc.date.available.fl_str_mv 2016-06-02T13:36:33Z
2016-06-03T12:34:16Z
dc.date.issued.fl_str_mv 2016
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
format article
status_str publishedVersion
dc.identifier.citation.fl_str_mv MENDOZA, Yaxelis; et al. HIV-1 Antiretroviral Drug Resistance Mutations in Treatment Naïve and Experienced Panamanian Subjects: Impact on National Use of EFV-Based Schemes. Plos One, v.11, n.4, 19, Apr. 2016.
dc.identifier.uri.fl_str_mv https://www.arca.fiocruz.br/handle/icict/14427
dc.identifier.issn.pt_BR.fl_str_mv 1932-6203
dc.identifier.doi.pt_BR.fl_str_mv 10.1371/journal. pone.0154317
identifier_str_mv MENDOZA, Yaxelis; et al. HIV-1 Antiretroviral Drug Resistance Mutations in Treatment Naïve and Experienced Panamanian Subjects: Impact on National Use of EFV-Based Schemes. Plos One, v.11, n.4, 19, Apr. 2016.
1932-6203
10.1371/journal. pone.0154317
url https://www.arca.fiocruz.br/handle/icict/14427
dc.language.iso.fl_str_mv eng
language eng
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.publisher.none.fl_str_mv Public Library of Science
publisher.none.fl_str_mv Public Library of Science
dc.source.none.fl_str_mv reponame:Repositório Institucional da FIOCRUZ (ARCA)
instname:Fundação Oswaldo Cruz (FIOCRUZ)
instacron:FIOCRUZ
instname_str Fundação Oswaldo Cruz (FIOCRUZ)
instacron_str FIOCRUZ
institution FIOCRUZ
reponame_str Repositório Institucional da FIOCRUZ (ARCA)
collection Repositório Institucional da FIOCRUZ (ARCA)
bitstream.url.fl_str_mv https://www.arca.fiocruz.br/bitstream/icict/14427/1/gonzalo_bello_etal_IOC_2016.PDF
https://www.arca.fiocruz.br/bitstream/icict/14427/2/license.txt
https://www.arca.fiocruz.br/bitstream/icict/14427/3/gonzalo_bello_etal_IOC_2016.PDF.txt
bitstream.checksum.fl_str_mv 9ac1aecdba0a8337eef8acb1440348db
5a560609d32a3863062d77ff32785d58
83ecd2fc071497f6e5f2cb52f404be0c
bitstream.checksumAlgorithm.fl_str_mv MD5
MD5
MD5
repository.name.fl_str_mv Repositório Institucional da FIOCRUZ (ARCA) - Fundação Oswaldo Cruz (FIOCRUZ)
repository.mail.fl_str_mv repositorio.arca@fiocruz.br
_version_ 1813008843029872640

Registros relacionados